2023

1. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

   Journal of Headache and Pain, Vol. 24, Núm. 1